Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00385710 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorStudy Identification, Study Status, Referencesv7
MinorRe-verified, no change to tracked fieldsv6
NotablePrimary endpoint revisedTrial status: Active, Not Recruiting to Completed · Primary and study completion dates changed from estimate of Aug 2010 to Jul 2010 · Interventions: valproic acid (Drug) to Placebo (Drug), valproic acid (Drug) · 2 morev5Show 5 more changesShow less
Trial status: Active, Not Recruiting to Completed
Primary and study completion dates changed from estimate of Aug 2010 to Jul 2010
Interventions: valproic acid (Drug) to Placebo (Drug), valproic acid (Drug)
MinorTrial status: Recruiting to Active, Not RecruitingEnrollment target: estimated 36 to confirmed 28 · Primary completion date: Aug 2010 · Completion date: Jun 2009 to Aug 2010 · 4 morev4Show 7 more changesShow less
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 4 · Start date: Oct 2006 to Nov 2006v2Show 2 more changesShow less
Study sites: 0 to 4
Start date: Oct 2006 to Nov 2006
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Progressive Supranuclear Palsy (PSP) is a relentlessly progressive neurodegenerative disorder, clinically characterized by parkinsonism with prominent axial involvement and postural instability, bulbar symptoms, supranuclear ophthalmoplegia, and executive dysfunction. Abnormal neuronal and glial tau aggregations affecting the basal ganglia and selective brainstem structures result in dysfunction of the five frontosubcortical circuits and brainstem functions. There is no effective treatment for PSP. One of the key feature in the aggregation of tau is its phosphorylation by kinases such as glycogen synthase kinase 3b (GSK3b). Recent reports have shown that valproic acid was able to inhibit the activity of GSK3b and could exert a neuroprotective effect through this inhibition. The investigators thus decided to conduct this controlled study to assess the putative neuroprotective effects in patients with PSP.